Search Results - "Perez, John L."

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents by Frenck, Robert W, Klein, Nicola P, Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L, Walter, Emmanuel B, Senders, Shelly, Bailey, Ruth, Swanson, Kena A, Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V, Cooper, David, Jennings, Timothy, Brandon, Donald M, Thomas, Stephen J, Türeci, Özlem, Tresnan, Dina B, Mather, Susan, Dormitzer, Philip R, Şahin, Uğur, Jansen, Kathrin U, Gruber, William C

“…This randomized trial of the BNT162b2 vaccine involved 2260 adolescents 12 to 15 years of age. Similar levels of antibody to SARS-CoV-2 were elicited in the…”
Get full text

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine by John L. Perez, Judith Absalon, Johannes Beeslaar, Paul Balmer, Kathrin U. Jansen, Thomas R. Jones, Shannon Harris, Laura J. York, Qin Jiang, David Radley, Annaliesa S. Anderson, Graham Crowther, Joseph J. Eiden

“…Introduction: Given the characteristics of meningococcal carriage and transmission and the sudden, often severe onset and long-term consequences of disease,…”
Get full text

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial by Richmond, Peter C, Dr, Marshall, Helen S, MBBS, Nissen, Michael D, MBBS, Jiang, Qin, MS, Jansen, Kathrin U, PhD, Garcés-Sánchez, Maria, MD, Martinón-Torres, Federico, PhD, Beeslaar, Johannes, MD, Szenborn, Leszek, MD, Wysocki, Jacek, MD, Eiden, Joseph, MD, Harris, Shannon L, PhD, Jones, Thomas R, PhD, Perez, John L, MD

“…Summary Background Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently…”
Get full text

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years by Borja-Tabora, Charissa Fay Corazon, Peyrani, Paula, Webber, Chris, Van der Wielen, Marie, Cheuvart, Brigitte, De Schrevel, Nathalie, Bianco, Veronique, Aris, Emmanuel, Cutler, Mark, Li, Ping, Perez, John L

“…Abstract Background A previous phase 2 study demonstrated the immunogenicity of a single dose of meningococcal A, C, W, Y-tetanus toxoid conjugate (MenACWY-TT)…”
Get full text

Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial by Marshall, Helen S, Dr, Richmond, Peter C, MBBS, Beeslaar, Johannes, MD, Jiang, Qin, MS, Jansen, Kathrin U, PhD, Garcés-Sánchez, Maria, PhD, Martinón-Torres, Federico, PhD, Szenborn, Leszek, MD, Wysocki, Jacek, Prof, Eiden, Joseph, MD, Harris, Shannon L, PhD, Jones, Thomas R, PhD, Lee, Su-San, BSc, Perez, John L, MD

“…Summary Background Bivalent rLP2086 is a recombinant factor H binding protein-based vaccine approved in the USA for prevention of meningococcal serogroup B…”
Get full text

Meningococcal serogroup B vaccines: Estimating breadth of coverage by Donald, Robert G. K., Hawkins, Julio Cesar, Hao, Li, Liberator, Paul, Jones, Thomas R., Harris, Shannon L., Perez, John L., Eiden, Joseph J., Jansen, Kathrin U., Anderson, Annaliesa S.

“…Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity…”
Get full text

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age by Vesikari, Timo, Peyrani, Paula, Webber, Chris, Van Der Wielen, Marie, Cheuvart, Brigitte, De Schrevel, Nathalie, Aris, Emmanuel, Cutler, Mark, Li, Ping, Perez, John L.

“…This phase 3B, open-label, extension study (NCT01962207) evaluated long-term persistence of antibodies induced by the quadrivalent meningococcal vaccine…”
Get full text

Vaccination strategies for the prevention of meningococcal disease by Vuocolo, Scott, Balmer, Paul, Gruber, William C., Jansen, Kathrin U., Anderson, Annaliesa S., Perez, John L., York, Laura J.

“…Routine prophylactic vaccination and mass vaccination strategies have been used to control both endemic and epidemic disease caused by Neisseria meningitidis…”
Get full text

Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine by Quiambao, Beatriz, Peyrani, Paula, Li, Ping, Cutler, Mark W., Van Der Wielen, Marie, Perez, John L., Webber, Chris

“…A previous phase 3, randomized, multicenter study showed the immunogenicity of a primary vaccination of subjects aged 11 to 17 years with the quadrivalent…”
Get full text

Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data by Beeslaar, Johannes, Peyrani, Paula, Absalon, Judith, Maguire, Jason, Eiden, Joseph, Balmer, Paul, Maansson, Roger, Perez, John L.

“…Introduction An extensive clinical development program showed that the meningococcal serogroup B-factor H binding protein (MenB-FHbp) vaccine affords…”
Get full text

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses by Sahin, Ugur, Muik, Alexander, Derhovanessian, Evelyna, Vogler, Isabel, Kranz, Lena M., Vormehr, Mathias, Baum, Alina, Pascal, Kristen, Quandt, Jasmin, Maurus, Daniel, Brachtendorf, Sebastian, Lörks, Verena, Sikorski, Julian, Hilker, Rolf, Becker, Dirk, Eller, Ann-Kathrin, Grützner, Jan, Boesler, Carsten, Rosenbaum, Corinna, Kühnle, Marie-Cristine, Luxemburger, Ulrich, Kemmer-Brück, Alexandra, Langer, David, Bexon, Martin, Bolte, Stefanie, Karikó, Katalin, Palanche, Tania, Fischer, Boris, Schultz, Armin, Shi, Pei-Yong, Fontes-Garfias, Camila, Perez, John L., Swanson, Kena A., Loschko, Jakob, Scully, Ingrid L., Cutler, Mark, Kalina, Warren, Kyratsous, Christos A., Cooper, David, Dormitzer, Philip R., Jansen, Kathrin U., Türeci, Özlem

“…An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety,…”
Get full text

MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies by Beeslaar, Johannes, Absalon, Judith, Anderson, Annaliesa S., Eiden, Joseph J., Balmer, Paul, Harris, Shannon L., Jones, Thomas R., O’Neill, Robert E., Pregaldien, Jean-Louis, Radley, David, Maansson, Roger, Ginis, John, Srivastava, Amit, Perez, John L.

“…Introduction Two phase 3 studies in adolescents and young adults demonstrated that MenB-FHbp, a meningococcal serogroup B (MenB) vaccine, elicits protective…”
Get full text

Greater Effect of Highly Active Antiretroviral Therapy on Survival in People Aged ⩾50 Years Compared with Younger People in an Urban Observational Cohort by Perez, John L., Moore, Richard D.

“…Although human immunodeficiency virus—infected people aged ⩾50 years have a blunted CD4 cell recovery when receiving highly active antiretroviral therapy…”
Get full text

A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults by Sheldon, Eric, Schwartz, Howard, Jiang, Qin, Giardina, Peter C., Perez, John L.

“…Neisseria meningitidis serogroup B (MnB) is a significant cause of invasive meningococcal disease, but no broadly protective vaccine is yet approved. We…”
Get full text

A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children by Cutland, Clare L., Peyrani, Paula, Webber, Chris, Newton, Ryan, Cutler, Mark, Perez, John L.

“…•We report immune persistence up to 5 y post MenACWY-TT vaccination of 12–14-mo-olds.•Immune responses declined over time but were higher at 5 y vs before…”
Get full text

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial by Thomas, Stephen J., Perez, John L., Lockhart, Stephen P., Hariharan, Subramanian, Kitchin, Nicholas, Bailey, Ruth, Liau, Katherine, Lagkadinou, Eleni, Türeci, Özlem, Şahin, Ugur, Xu, Xia, Koury, Kenneth, Dychter, Samuel S., Lu, Claire, Gentile, Teresa C., Gruber, William C.

“…•We show BNT162b2 vaccine ph or phase 3 data from participants with baseline history of past/active neoplasm.•Efficacy and safety were evaluated through up to…”
Get full text

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial by Peterson, James, Drazan, Daniel, Czajka, Hanna, Maguire, Jason, Pregaldien, Jean-Louis, Seppa, IIkka, Maansson, Roger, O'Neill, Robert, Balmer, Paul, Jodar, Luis, Jansen, Kathrin U, Anderson, Annaliesa S, Perez, John L, Beeslaar, Johannes

“…Meningococcal serogroups A, B, C, W, and Y cause nearly all meningococcal disease, and comprehensive protection requires vaccination against all five…”
Get full text

A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults by Ostergaard, Lars, Vesikari, Timo, Absalon, Judith, Beeslaar, Johannes, Ward, Brian J, Senders, Shelly, Eiden, Joseph J, Jansen, Kathrin U, Anderson, Annaliesa S, York, Laura J, Jones, Thomas R, Harris, Shannon L, O’Neill, Robert, Radley, David, Maansson, Roger, Prégaldien, Jean-Louis, Ginis, John, Staerke, Nina B, Perez, John L

“…In two phase 3 studies, a bivalent meningococcal B vaccine was shown to elicit serum bactericidal activity against 14 meningococcal B test strains in…”
Get full text

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus by Madhi, Shabir A., Anderson, Annaliesa S., Absalon, Judith, Radley, David, Simon, Raphael, Jongihlati, Babalwa, Strehlau, Renate, van Niekerk, Anika M., Izu, Alane, Naidoo, Niree, Kwatra, Gaurav, Ramsamy, Yogandree, Said, Mohamed, Jones, Stephanie, Jose, Lisa, Fairlie, Lee, Barnabas, Shaun L., Newton, Ryan, Munson, Samantha, Jefferies, Zahra, Pavliakova, Danka, Silmon de Monerri, Natalie C., Gomme, Emily, Perez, John L., Scott, Daniel A., Gruber, William C., Jansen, Kathrin U.

“…A hexavalent capsular polysaccharide glycoconjugate vaccine (GBS6) was studied in pregnant women. Maternal anti-CPS antibodies were elicited, and humoral…”
Get full text

A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults by Drazan, Daniel, Czajka, Hanna, Maguire, Jason D., Pregaldien, Jean-Louis, Maansson, Roger, O'Neill, Robert, Anderson, Annaliesa S, Balmer, Paul, Beeslaar, Johannes, Perez, John L

“…•The MenB-FHbp vaccine is given on a 2-dose (0,6 mo) or 3-dose (0, 1–2, 6 mo) series.•Immunogenicity and safety of the 2-dose series in a phase 3 study are…”
Get full text